**Author details**

Wael I. Ibraheem\* and Reghunathan S. Preethanath College of Dentistry, Jazan University, Jazan, Kingdom of Saudi Arabia

\*Address all correspondence to: dr.wael007@yahoo.com; wibraheem@jazanu.edu.sa

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**53**

*Host Modulation*

**References**

1990;**322**(6):373

*DOI: http://dx.doi.org/10.5772/intechopen.91615*

[1] Williams RC. Periodontal disease. The New England Journal of Medicine. [9] Williams RC, Jeffcoat MK, Howell TH, et al. Indomethacin or flurbiprofen treatment of periodontitis in beagles: Comparison of effect on bone loss. Journal of Periodontal Research. 1987;**22**:403

[10] Williams RC, Jeffcoat MK, Howell TH, et al. Altering the progression of human alveolar bone loss with the non-steroidal antiinflammatory drug flurbiprofen. Journal of Periodontology. 1989;**60**:485

[11] Howell TH, Jeffcoat MK,

Research. 1991;**26**:498

2003;**74**:57

Goldhaber P, et al. Inhibition of alveolar bone loss in beagles with the NSAID naproxen. Journal of Periodontal

[12] Vardar S, Baylas H, Huseyinov A. Effects of selective cyclooxygenase-2 inhibition on gingival tissue levels of prostaglandin E2 and prostaglandin F2a and clinical parameters of chronic periodontitis. Journal of Periodontology.

[13] Williams RC, Jeffcoat MK, Howell TH, et al. Three year trial of flurbiprofen treatment in humans: Post-treatment period [abstract 1617]. Journal of Dental Research. 1991;**70**:468

[14] Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research TeamAnnals of the New York Academy of Sciences. 1999;**878**:335

[15] Preshaw PM, Novak MJ, Mellonig J, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. Journal of Periodontology. 2008;**79**(3):440

[16] Needleman I, Suvan J,

Gilthorpe MS, et al. A randomizedcontrolled trial of low-dose doxycycline for periodontitis in smokers. Journal of Clinical Periodontology. 2007;**34**(4):325

[2] Golub LM, Suomalainen K, Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Current Opinion

[3] Weinreb M, Quartuccio H,

analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. Journal of Periodontal Research. 1994;**29**:35

Periodontology. 2000;**71**:1158

1995;**66**:211

2005;**182**(8):413

[5] Reddy MS, Weatherford TW, Smith CA, et al. Alendronate treatment of naturally-occurring periodontitis in beagle dogs. Journal of Periodontology.

[6] Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: A possible association. The Medical Journal of Australia.

[7] Grenier D, Plamondon P,

Periodontology. 2002;**73**:79

[8] Buduneli N, Vardar S, Atilla G, et al. Gingival crevicular fluid matrix metalloproteinase-8 levels following adjunctive use of meloxicam and initial phase of periodontal therapy. Journal of

Periodontology. 2002;**73**:103-109

Sorsa T, et al. Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. Journal of

Seedor JG, et al. Histomorphometrical

[4] Nakaya H, Osawa G, Iwasaki N, et al. Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells. Journal of

in Dentistry. 1992;**2**:80
